Instructions Aminocaproic acid solution for infusions 5% bottle 100 ml
Composition
active ingredient: 1 ml of solution contains 50 mg of aminocaproic acid;
Excipients: sodium chloride, water for injections.
Dosage form
Solution for infusion.
Main physicochemical properties: colorless transparent liquid.
Pharmacotherapeutic group
Antihemorrhagic agents. Fibrinolysis inhibitors.
ATX code B02A A01.
Pharmacological properties
Pharmacodynamics
Aminocaproic acid solution has a hemostatic, antifibrinolytic effect in bleeding caused by increased fibrinolysis. Its action is associated with the blockade of plasminogen activators and partial inhibition of the effect of plasmin. The drug also inhibits biogenic polypeptides - kinins. It promotes the stabilization of fibrin and its deposition in the vascular bed, induces platelet and erythrocyte aggregation.
Aminocaproic acid has antiallergic, antiviral effects, enhances the detoxification function of the liver. It inhibits the proteolytic activity associated with the influenza virus. Aminocaproic acid has an inhibitory effect on the early stages of the interaction of the virus with sensitive cells, and also suppresses the proteolytic activity of hemagglutinin. As a result, a functionally active protein of the influenza virus, which ensures its infectious activity, is not created, and the amount of daughter infectious virus is reduced. Aminocaproic acid not only exhibits antiviral activity, but also improves some cellular and humoral indicators of specific and nonspecific protection of the body in respiratory viral infections.
Pharmacokinetics
When administered intravenously, the effect occurs after 15-20 minutes. 40-60% of the administered amount is rapidly excreted by the kidneys, after 4 hours it is excreted in the urine. In case of impaired renal excretory function, the concentration of aminocaproic acid in the blood increases significantly.
Indication
Bleeding after surgical operations and various pathological conditions associated with increased fibrinolytic activity of blood and tissues.
To prevent the development of secondary hypofibrinogenemia during massive transfusions of preserved blood.
Treatment and prevention of influenza and acute respiratory viral infections in children and adults.
Contraindication
Hypersensitivity to the drug. Tendency to thrombosis and thromboembolic diseases; thromboembolism; coagulopathy due to diffuse intravascular coagulation; kidney disease with impaired function; renal failure; hematuria; pregnancy, childbirth and breastfeeding; severe ischemic heart disease. Cerebral circulatory disorders.
Interaction with other medicinal products and other types of interactions
The effect of the drug is weakened by anticoagulants and antiplatelet agents of direct and indirect action. Joint use with estrogen-containing contraceptives, blood clotting factor IX increases the risk of thromboembolism. Use with caution in patients taking retinoids (including tretinoin).
Application features
When administered intravenously, it is necessary to monitor the coagulogram, especially in ischemic heart disease, after myocardial infarction, in pathological processes in the liver. In case of hematuria, the drug is not recommended due to the risk of acute renal failure. It is recommended to exclude fatty foods during treatment with the drug.
Use with caution in patients with heart disease. If it is necessary to use the drug in patients with heart disease, it is recommended to monitor the level of creatine phosphokinase in the blood plasma. Do not use the remaining drug.
Use during pregnancy or breastfeeding
The drug is contraindicated during pregnancy. It is not advisable to use it in women for the prevention of increased blood loss during childbirth due to the possible occurrence of thromboembolic complications. If necessary, breastfeeding should be discontinued.
The ability to influence the reaction speed when driving or working with other mechanisms
During treatment, you should refrain from driving vehicles and performing potentially dangerous activities due to possible adverse reactions from the central nervous system.
Method of administration and doses
Aminocaproic acid solution should be administered orally or intravenously.
Internally, adults should be prescribed 5 g (100 ml) of the drug, then 1 g (20 ml) every hour for 8 hours until bleeding stops completely.
If it is necessary to achieve a rapid effect (acute hypofibrinogenemia), administer intravenously drip up to 100 ml of solution (5 g) at a rate of 50-60 drops per minute for 15-30 minutes. During the first hour, administer in a dose of 4-5 g, and in case of prolonged bleeding - until it stops completely - administer 1 g every hour, but not more than 8 hours.
If bleeding recurs, repeat the administration of the 5% solution.
Children.
With a moderate increase in fibrinolytic activity, Aminocaproic Acid should be administered to children once at a dose of 0.05 g/kg of body weight per day. The dose, depending on age, is:
– from 2 to 6 years: single dose – 2.5-5 ml, daily dose – 15-30 ml;
– from 7 to 10 years: single dose – 5-7 ml, daily dose – 30-45 ml;
– from 11 to 18 years: single dose – 7-14 ml, daily dose – 45-90 ml.
In acute bleeding, the doses are:
– for children under 1 year of age: single dose – 5 ml, daily dose – 30 ml;
– from 2 to 4 years: single dose – 5-7.5 ml, daily dose – 30-45 ml;
– from 5 to 8 years: single dose – 7.5-10 ml, daily dose – 45-60 ml;
– from 9 to 10 years: single dose – 15 ml, daily dose – 90 ml;
– from 11 to 14 years: single dose – 20 ml, daily dose – 120 ml;
– from 15 to 18 years: single dose – 28 ml, daily dose – 160 ml.
The course of treatment is from 3 to 14 days.
For the prevention and treatment of influenza and acute respiratory viral infections, the drug should be used orally and topically (0.5-1.0 ml in the nose 3-4 times a day).
The drug should be administered orally to children in doses:
– for children under 2 years old – 1-2 g (20-40 ml of 5% solution per day) – 1-2 teaspoons 4 times a day (0.02-0.04 g/kg – single dose), can be added to food or drinks;
– children aged 2 to 6 years – 2-4 g (40-80 ml of 5% solution per day) – 1-2 tablespoons 4 times a day;
– children over 7 years of age and adults – 4-5 g (80-100 ml of 5% solution per day), dividing the daily dose into 4 doses.
For more accurate dosing of the solution, it is advisable to use a medical syringe without a needle with a volume of 10 or 20 ml.
At the same time, topical application of aminocaproic acid is justified. It is recommended to place cotton swabs moistened with a 5% solution of aminocaproic acid in the nasal passages for 5-10 minutes every 3-4 hours, or to instill (drop) the drug in the nasal passages at the indicated times.
3-5 drops of solution into each nasal passage.
Aminocaproic acid can be used in combination with other antiviral drugs and interferon and its inducers, if necessary.
Intranasal instillations of aminocaproic acid (3-4 times a day) are advisable to be carried out during the epidemic period for the purpose of prevention, which should be supplemented with enteral (as in treatment) use of the drug in foci of infection upon contact with the patient.
The duration of oral administration of aminocaproic acid for influenza and acute respiratory viral infections is 3-7 days.
The duration of treatment depends on the severity of the disease and is determined by the doctor individually. The doctor may also adjust the dose and prescribe a repeated course of treatment.
Children
There is no data on restrictions on the use of the drug in children.
Overdose
Sudden decrease in fibrinolytic activity of the blood. Severe side effects: dizziness, nausea, diarrhea, skin rash, orthostatic hypotension, convulsions, headache, nasal congestion, acute renal failure, rhabdomyolysis, myoglobinuria. Increased adverse reactions, thromboembolism, embolism. With prolonged use (more than 6 days) of high doses (for adults - more than 24 g per day) - hemorrhages.
Treatment: In case of overdose, discontinue administration of the drug and provide appropriate symptomatic therapy.
Adverse reactions
Cardiovascular system: orthostatic hypotension, subendocardial hemorrhage, bradycardia, arrhythmias.
On the part of the digestive system: nausea, diarrhea, vomiting.
From the side of the blood coagulation system: blood clotting disorders, with prolonged use (over 6 days) of high doses (for adults - over 24 g per day) - hemorrhages.
From the side of the central nervous system: headache, dizziness, tinnitus, convulsions.
On the part of the immune system: hypersensitivity reactions, including allergic reactions, rash, nasal congestion, catarrhal phenomena of the upper respiratory tract.
General disorders: changes at the injection site.
Other: myoglobinuria, rhabdomyolysis, acute renal failure. If the rate of administration is exceeded, bradycardia and extrasystole are possible.
Expiration date
3 years.
Storage conditions
Store at a temperature not exceeding 25 °C. Store in the original packaging. Keep out of the reach of children. Store bottles in an upright position.
Packaging
100 ml in bottles or containers; 2 ml, 4 ml in single-dose containers No. 10 in a pack.
Vacation category
According to the recipe.
Producer
LLC "Yuria-Pharm".
Location of the manufacturer and its business address
18030, Ukraine, Cherkasy, Verbovetskogo St., 108.
Phone/fax: (044) 281-01-01.
